Inari MedicalNARI
NARI
About: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Employees: 1,300
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
3% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 38
0.34% less ownership
Funds ownership: 95.95% [Q2] → 95.61% (-0.34%) [Q3]
1% less funds holding
Funds holding: 242 [Q2] → 239 (-3) [Q3]
14% less capital invested
Capital invested by funds: $2.69B [Q2] → $2.3B (-$387M) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 86
21% less call options, than puts
Call options by funds: $4.53M | Put options by funds: $5.72M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$63
21%
downside
Avg. target
$76
4%
downside
High target
$80
1%
upside
6 analyst ratings
1 positive
17%
5 neutral
83%
0 negative
0%
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target | 1%upside $80 | Equal-Weight Downgraded | 7 Jan 2025 |
Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target | 1%upside $80 | Neutral Maintained | 7 Jan 2025 |
Canaccord Genuity William Plovanic 72% 1-year accuracy 34 / 47 met price target | 1%upside $80 | Hold Downgraded | 7 Jan 2025 |
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target | 1%upside $80 | Neutral Downgraded | 7 Jan 2025 |
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target | 21%downside $63 | Hold Maintained | 18 Dec 2024 |
Financial journalist opinion
Based on 22 articles about NARI published over the past 30 days
Neutral
Accesswire
1 day ago
Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Positive
Zacks Investment Research
4 days ago
Are You Looking for a Top Momentum Pick? Why Inari Medical, Inc. (NARI) is a Great Choice
Does Inari Medical, Inc. (NARI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Neutral
Business Wire
1 week ago
INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.
Neutral
PRNewsWire
1 week ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inari Medical, Inc. - NARI
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Inari Medical, Inc. (Nasdaq: NARI ), relating to the proposed merger with Stryker.
Positive
Schaeffers Research
1 week ago
Medical Stock Surges to Multi-Year Highs on Acquisition News
Shares of Inari Medical Inc (NASDAQ:NARI) are 21.5% higher in premarket trading, on track to open at nearly $79 amid news that Stryker (SYK) agreed to acquire the medical device maker in an all-cash deal worth roughly $4.9 billion, or $80 per share.
Positive
Zacks Investment Research
1 week ago
Inari Medical (NARI) Soars 30.6%: Is Further Upside Left in the Stock?
Inari Medical (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Positive
Investopedia
1 week ago
Inari Shares Skyrocket As Stryker Will Acquire Medical Device Maker for $4.9B
Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker (SYK) proved to be true.
Charts implemented using Lightweight Charts™